EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Ahmet Sencer Ergin iD, Burcin Cakan Demirel iD, Sahin Bedir iD, Nida Sünnetci Arıkan iD, Alparslan Saylar iD, Ali Karabulut, Nihat Bugdayci, Tevhide Bilgen Özcan, Hüsniye Esra Pasaoglu

Journal of Clinical Medicine · 28.06.2026 · 15 (13) · 5039

DOI: 10.3390/jcm15135039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.06.2026. Verfasst von Ahmet Sencer Ergin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Bagcilar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Turkey. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Predicting tumor regression following neoadjuvant chemoradiotherapy (nCRT) remains a major challenge in the management of locally advanced rectal cancer (LARC). Readily available inflammatory biomarkers may provide useful information regarding treatment response.

Methods

This retrospective single-center study included 88 patients with stage II–III rectal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative-intent surgery between 2017 and 2025. Patients were classified according to the College of American Pathologists tumor regression grading system as CAP 0 (pathological complete response, n = 22), CAP 2 (partial response, n = 50), or CAP 3 (poor/no response, n = 16). Pretreatment C-reactive protein, carcinoembryonic antigen (CEA), neutrophil, platelet, monocyte, and lymphocyte counts, together with NLR, PLR, and PIV, were compared across groups. Receiver operating characteristic and logistic regression analyses were performed for pathological complete response (pCR).

Results

None of the evaluated biomarkers differed significantly across CAP groups. The smallest omnibus p-values were observed for neutrophil count (p = 0.052), monocyte count (p = 0.075), and CEA (p = 0.088). Monocyte count showed the highest discriminatory performance for pathological complete response (AUC = 0.663), followed by CEA (AUC = 0.640). In sensitivity analyses adjusted for baseline clinical T stage and receipt of total neoadjuvant therapy, CEA, neutrophil count, and monocyte count were not independently associated with pathological complete response. More favorable tumor regression was associated with lower residual tumor burden and reduced nodal involvement.

Conclusions

Pretreatment inflammatory biomarkers showed biologically plausible numerical patterns across tumor regression groups, but their discriminatory and independent predictive performance was limited. These markers should not be considered stand-alone clinical prediction tools and should be validated within larger, multimodal prospective models.

Schlagwörter

Stichwörter der Autor:innen

carcinoembryonic antigeninflammation biomarkersneoadjuvant chemoradiotherapypathological complete responserectal cancertumor regression grade

Autor:innen und Institutionen

  • Department of General Surgery, Bagcilar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Turkey.
  • Department of Medical Oncology, Medipol Mega University Hospital, Istanbul Medipol University, 34124 Istanbul, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Gaziosmanpaşa Hospital, Istinye University, 34250 Istanbul, Turkey.
  • Department of Radiation Oncology, Bagcilar Training and Research Hospital, University of Health Sciences, 34164 Istanbul, Turkey.
  • Department of Pathology, Bagcilar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Turkey.

ORCID-Profile: Ahmet Sencer Ergin, Burcin Cakan Demirel, Sahin Bedir, Nida Sünnetci Arıkan, Alparslan Saylar

Zitieren

APA

Ergin, A. S., Cakan Demirel, B., Bedir, S., Sünnetci Arıkan, N., Saylar, A., Karabulut, A., Bugdayci, N., Özcan, T. B., & Pasaoglu, H. E. (2026). Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Journal of Clinical Medicine, 15(13), 5039. https://doi.org/10.3390/jcm15135039

Vancouver

Ergin AS, Cakan Demirel B, Bedir S, Sünnetci Arıkan N, Saylar A, Karabulut A, et al. Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Journal of Clinical Medicine. 2026;15(13):5039. doi:10.3390/jcm15135039

BibTeX
@article{Ergin2026,
  author = {Ergin, Ahmet Sencer and Cakan Demirel, Burcin and Bedir, Sahin and Sünnetci Arıkan, Nida and Saylar, Alparslan and Karabulut, Ali and Bugdayci, Nihat and Özcan, Tevhide Bilgen and Pasaoglu, Hüsniye Esra},
  title = {Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5039},
  doi = {10.3390/jcm15135039}
}
Kostenlos starten →